Following the March 2026 Tavneos vasculitis drug safety alert from the FDA, we are investigating possibly related deaths and liver injuries legal cases to be filed against the drug company Amgen on behalf of patients using Tavneos who developed serious liver side effects or the families of those patients who died. Tavneos Vasculitis Drug … [Read more...]
Pleurectomy/Decortication Safe in Select Patients With Pleural Mesothelioma
Pleurectomy/decortication can be completed safely in select patients with pleural mesothelioma with low postoperative mortality, according to findings from a study published in The Annals of Thoracic Surgery. “Our findings show that pleurectomy/decortication can be done safely when patients are carefully selected and surgery is tailored to … [Read more...]
Ozempic Eye Stroke Side Effect Rates Study 2026
Non-arteritic anterior ischemic optic neuropathy (NAION) is a vision-related drug side effect commonly referred to as an "eye stroke". In this post, we focus on a new Ozempic eye stroke side effect rates study published in the March 2026 British Journal of Ophthalmology article, "Ischemic optic neuropathy with semaglutide: global observational … [Read more...]
NAION Ozempic Side-Effect Warning: Novo Nordisk Failure
We have written about the NAION Ozempic side-effect warning issue several times over the past year-and-a-half, and have repeatedly pointed out that non-arteritic anterior ischemic optic neuropathy, or NAION, is linked to semaglutide. Moreover, we noted that semaglutide is the active ingredient in the currently available Novo Nordisk semaglutide … [Read more...]
Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743
Opdivo (nivolumab) Plus Yervoy (ipilimumab) Treatments: CheckMate 743 Study [Opdivo plus Yervoy treatments have] demonstrated long-term, durable survival benefit as first-line treatment in patients with various solid tumor types. The randomized phase III CheckMate 743 study demonstrated significant overall survival (OS) benefit with [Opdivo plus … [Read more...]
NAION Vision Loss With Ozempic, Wegovy, and Rybelsus: New Medical Evidence in 2026
Ozempic, Wegovy, and Rybelsus are semaglutide-containing drugs from Novo Nordisk. Starting in 2024, there have been reports of non-arteritic anterior ischemic optic neuropathy, or NAION, associated with these semaglutide-containing drugs. And there is new medical evidence in 2026 regarding NAION vision loss with Ozempic, Wegovy, and … [Read more...]
Rybelsus Lawsuits for Pancreatitis Death Cases
We are investigating Rybelsus lawsuits, with a focus on cases of hemorrhagic pancreatitis or necrotizing pancreatitis involving death. Those Rybeslus pancreatitis death cases would be filed against the responsible pharmaceutical company, Novo Nordisk. The best Rybelsus lawsuits would be for people who were diagnosed with hemorrhagic pancreatitis … [Read more...]
Pembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study
Background: Pembrolizumab (anti-PD-1 antibody) plus lenvatinib (multityrosine kinase inhibitor) showed high clinical activity in PEMMELA cohort 1 in patients with pleural mesothelioma pre-treated with platinum-based chemotherapy. This study (cohort 2) aimed to investigate the clinical activity of this combination in patients with pleural … [Read more...]
Depo-Provera Legal Compensation Cases After Meningioma Warning Added to Drug Label in 2025
Question: Can Depo-Provera legal compensation cases still be filed after a meningioma warning was added in December 2025 to the Depo-Provera drug label? Short Answer: Yes, new Depo-Provera lawsuits can be filed if you received a Depo-Provera injection before December 2025, and were diagnosed with meningioma any time after those … [Read more...]
Semaglutide Deep Vein Thrombosis Case Information: 2026 Medical Journal Article
A 2026 medical journal article, which presented some semaglutide deep vein thrombosis case information, is of interest to us because Ozempic, Wegovy, and Rybelsus — three relatively new semaglutide-containing drugs — have been associated with a significantly increased risk of blood clots. We have been investigating Ozempic, Wegovy, and Rybelsus … [Read more...]
- 1
- 2
- 3
- …
- 25
- Next Page »